Compound ID | 1270
Class: 13-substituted cycloberberine derivative
Spectrum of activity: | Gram-positive |
Details of activity: | High potency against methicillin-sensitive (MSSA) and resistant strains of S. aureus (MRSA). |
Institute where first reported: | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing, China |
Year first mentioned: | 2019 |
Highest developmental phase: | Preclinical |
Development status: | Active |